449 related articles for article (PubMed ID: 29154989)
1. Targeting bromodomain and extraterminal proteins in breast cancer.
Sahni JM; Keri RA
Pharmacol Res; 2018 Mar; 129():156-176. PubMed ID: 29154989
[TBL] [Abstract][Full Text] [Related]
2. The emerging role of BET inhibitors in breast cancer.
Andrikopoulou A; Liontos M; Koutsoukos K; Dimopoulos MA; Zagouri F
Breast; 2020 Oct; 53():152-163. PubMed ID: 32827765
[TBL] [Abstract][Full Text] [Related]
3. Impact of structurally diverse BET inhibitors on SIRT1.
Tenhunen J; Kokkola T; Huovinen M; Rahnasto-Rilla M; Lahtela-Kakkonen M
Gene; 2020 May; 741():144558. PubMed ID: 32165310
[TBL] [Abstract][Full Text] [Related]
4. Developing effective combination therapy for pancreatic cancer: An overview.
Miller AL; Garcia PL; Yoon KJ
Pharmacol Res; 2020 May; 155():104740. PubMed ID: 32135247
[TBL] [Abstract][Full Text] [Related]
5. Natural inhibitors of PI3K/AKT signaling in breast cancer: emphasis on newly-discovered molecular mechanisms of action.
Safdari Y; Khalili M; Ebrahimzadeh MA; Yazdani Y; Farajnia S
Pharmacol Res; 2015 Mar; 93():1-10. PubMed ID: 25533812
[TBL] [Abstract][Full Text] [Related]
6. Targeting ETS1 with RNAi-based supramolecular nanoassemblies for multidrug-resistant breast cancer therapy.
Wu M; Liu X; Jin W; Li Y; Li Y; Hu Q; Chu PK; Tang G; Ping Y
J Control Release; 2017 May; 253():110-121. PubMed ID: 28302581
[TBL] [Abstract][Full Text] [Related]
7. Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors.
Ramadoss M; Mahadevan V
Drug Discov Today; 2018 Jan; 23(1):76-89. PubMed ID: 28943305
[TBL] [Abstract][Full Text] [Related]
8. Bromodomain inhibitors: what does the future hold?
Bhattacharya S; Piya S; Borthakur G
Clin Adv Hematol Oncol; 2018 Jul; 16(7):504-515. PubMed ID: 30067623
[TBL] [Abstract][Full Text] [Related]
9. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
[TBL] [Abstract][Full Text] [Related]
10. BET Proteins as Attractive Targets for Cancer Therapeutics.
Sarnik J; Popławski T; Tokarz P
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681760
[TBL] [Abstract][Full Text] [Related]
11. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
12. BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer.
Genta S; Pirosa MC; Stathis A
Curr Oncol Rep; 2019 Feb; 21(2):13. PubMed ID: 30715616
[TBL] [Abstract][Full Text] [Related]
13. Molecular Pathways: Targeting the PI3K Pathway in Cancer-BET Inhibitors to the Rescue.
Stratikopoulos EE; Parsons RE
Clin Cancer Res; 2016 Jun; 22(11):2605-10. PubMed ID: 27250929
[TBL] [Abstract][Full Text] [Related]
14. OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
Berenguer-Daizé C; Astorgues-Xerri L; Odore E; Cayol M; Cvitkovic E; Noel K; Bekradda M; MacKenzie S; Rezai K; Lokiec F; Riveiro ME; Ouafik L
Int J Cancer; 2016 Nov; 139(9):2047-55. PubMed ID: 27388964
[TBL] [Abstract][Full Text] [Related]
15. Advances in molecular mechanisms of drugs affecting abnormal glycosylation and metastasis of breast cancer.
Liu H; Ma L; Lin J; Cao B; Qu D; Luo C; Huang W; Han L; Xu H; Wu Z; Xu R; Zhang D
Pharmacol Res; 2020 May; 155():104738. PubMed ID: 32151681
[TBL] [Abstract][Full Text] [Related]
16. Machine learning model for anti-cancer drug combinations: Analysis, prediction, and validation.
Zhou JB; Tang D; He L; Lin S; Lei JH; Sun H; Xu X; Deng CX
Pharmacol Res; 2023 Aug; 194():106830. PubMed ID: 37343647
[TBL] [Abstract][Full Text] [Related]
17. Bromodomain inhibitors, JQ1 and I-BET 762, as potential therapies for pancreatic cancer.
Leal AS; Williams CR; Royce DB; Pioli PA; Sporn MB; Liby KT
Cancer Lett; 2017 May; 394():76-87. PubMed ID: 28254412
[TBL] [Abstract][Full Text] [Related]
18. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
[TBL] [Abstract][Full Text] [Related]
20. Activation of ALDH1A1 in MDA-MB-468 breast cancer cells that over-express CYP2J2 protects against paclitaxel-dependent cell death mediated by reactive oxygen species.
Allison SE; Chen Y; Petrovic N; Zhang J; Bourget K; Mackenzie PI; Murray M
Biochem Pharmacol; 2017 Nov; 143():79-89. PubMed ID: 28756208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
